This multi-pronged approach allows the evaluation of newer molecular leads like HDAC inhibitors not only for cytotoxic potency but also for functional traits relevant to GBM aggressiveness: migration (ROM) and long-term survival (LR) under stress. The gene discussed is HDAC9; the disease is glioblastoma.